Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Prazosin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1B known ✓ | P35368 | 7/20 | 1.00 |
| ▸ | ADRA1A known ✓ | P35348 | 6/20 | 1.00 |
| ▸ | ADRA1D known ✓ | P25100 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | GLA | P06280 | 4/20 | 1.00 |
| ▸ | GAA | P10253 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | RAB9A | P51151 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prazosin SCHEMBL26524 | 1.00 | ADRA1B (1.00) | ADRA1BADRA1AKDM4EGLAGAA | |
| Prazosin SCHEMBL1172954 | 0.99 | ADRA1B (1.00) | ADRA1BADRA1AKDM4EGLAGAA | |
| Prazosin SCHEMBL41257 | 0.99 | ADRA1B (1.00) | ADRA1BADRA1AKDM4EGLAGAA | |
| Prazosin SCHEMBL29908896 | 0.99 | ADRA1B (1.00) | ADRA1BADRA1AKDM4EGLAGAA | |
| Prazosin SCHEMBL611396 | 0.99 | ADRA1B (1.00) | ADRA1BADRA1AKDM4EGLAGAA | |
| Prazosin SCHEMBL9663302 | 0.98 | KDM4E (1.00) | ADRA1BADRA1AKDM4EGLAGAA | |
| Prazosin SCHEMBL11656542 | 0.98 | KDM4E (1.00) | ADRA1BADRA1AKDM4EGLAGAA | |
| Prazosin SCHEMBL41258 | 0.98 | ADRA1B (0.96) | ADRA1BADRA1AKDM4EGLAGAA | |
| Prazosin SCHEMBL29157754 | 0.97 | ADRA1A (0.94) | ADRA1BADRA1AKDM4EGLAGAA | |
| SCHEMBL7797445 | 0.96 | ADRA1B (0.93) | ADRA1BADRA1AKDM4EGLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 335 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025091039-A1 | DEVICE AND METHOD FOR INJECTION OF AN ACTIVE AGENT | STAT THERAPEUTICS, INC. (US) | 2025-05-01 | — | — | WO | claimed |
| EP-3776738-B1 | CONNECTION ELEMENT, ARRANGEMENT AND ENERGY DISTRIBUTION SYSTEM | PHOENIX CONTACT GMBH & CO (DE) | 2024-06-26 | — | — | EP | claimed |
| US-11583544-B2 | Remote loading of sparingly water-soluble drugs into lipid vesicles | CELATOR PHARMACEUTICALS, INC. (US) | 2023-02-21 | — | — | US | claimed |
| EP-3454853-B1 | TREATMENT OF ALCOHOLISM AND DEPRESSION USING IBUDILAST | MEDICINOVA INC (US) | 2022-05-18 | — | — | EP | claimed |
| CN-114427735-A | Air conditioner control method, control device and nonvolatile storage medium | 珠海格力电器股份有限公司 | 2022-05-03 | — | — | CN | claimed |
| EP-4105935-B1 | DESIGN OF MOLECULES | RECURSION PHARMACEUTICALS INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260137691-A1 | WB3 FOR ANESTHESIA AND TREATING PAIN | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2026-05-21 | — | — | US | disclosed |
| CN-122048978-A | Space-time perception enhancement method, system and equipment for multi-frame image | 清华大学深圳国际研究生院 | 2026-05-15 | — | — | CN | disclosed |
| CN-122017242-A | Application of reagent for detecting marker in preparation of product for predicting prognosis of patient with triple negative breast cancer | 广东医科大学附属医院 | 2026-05-12 | — | — | CN | disclosed |
| US-20260116923-A1 | CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS | MERCK SHARP & DOHME LLC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4727552-A2 | PASSIVE PERMEABLE PCSK9 ANTAGONIST COMPOUNDS | Merck Sharp & Dohme LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4540267-B1 | CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20220098145-A1 | Carbamoyl Phenylalaninol Compounds and Uses Thereof | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2022-03-31 | — | — | US | disclosed |
| EP-3972589-A1 | NATRIURETIC PEPTIDE RECEPTOR A AGONISTS USEFUL FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES, KIDNEY DISEASE AND DIABETES | Merck Sharp & Dohme Corp. (US) | 2022-03-30 | — | — | EP | disclosed |
| EP-3972590-A1 | NATRIURETIC PEPTIDE RECEPTOR A AGONISTS USEFUL FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES, KIDNEY DISEASE AND DIABETES | Merck Sharp & Dohme Corp. (US) | 2022-03-30 | — | — | EP | disclosed |
| CN-114211593-A | Method for improving collapse force of permanent magnetic ferrite magnetic shoe | 中钢天源(马鞍山)通力磁材有限公司 | 2022-03-22 | — | — | CN | disclosed |
| EP-2502173-B1 | DESIGN OF MOLECULES | EXSCIENTIA LTD (GB) | 2022-03-16 | — | — | EP | disclosed |
| US-11260126-B2 | Acoustic driven drug delivery systems | UNIVERSITY OF OTAGO (NZ) | 2022-03-01 | — | — | US | disclosed |
| EP-3634964-B1 | PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | MERCK SHARP & DOHME (US) | 2022-02-23 | — | — | EP | disclosed |
| EP-3946303-A1 | FORMULATIONS | Synchroneuron Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098145-A1 | Carbamoyl Phenylalaninol Compounds and Uses Thereof | DNPEP, CPS1, BPHL | ADRA1B 3874/4885ADRA1A 3389/4885ADRA1D 4262/4885 |
| US-20260137691-A1 | WB3 FOR ANESTHESIA AND TREATING PAIN | WNT3, TRPV3, ADRB3 | ADRA1B 387/4885ADRA1A 296/4885ADRA1D 149/4885 |
| US-20260116923-A1 | CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS | IL1A, IL1B, IL1RN | ADRA1B 400/4885ADRA1A 354/4885ADRA1D 300/4885 |
| US-11260126-B2 | Acoustic driven drug delivery systems | LSS, LIPA, MTREX | ADRA1B 927/4885ADRA1A 560/4885ADRA1D 1374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.